Abstract The Cagritirz 15mg peptide pen constitutes a high-fidelity research compound comprising a synergistic blend of Cagrilintide and Tirzepatide. This dual-entity formulation allows for the simultaneous investigation of three distinct receptor pathways: the Glucagon-like Peptide-1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), and Amylin (AMY) receptors. By combining the “twincretin” mechanism of Tirzepatide with the non-incretin amylin agonism of Cagrilintide, this product serves as a critical tool for researchers exploring the next generation of metabolic modulation. It is specifically designed to elucidate the compounding effects of simultaneous hormone simulation on glycaemic control, lipolysis, and gastric motility in controlled laboratory environments.

Mechanism and Research Interest

Primary Biological Pathway: Tri-Agonist Synergism The primary research value of Cagritirz lies in its ability to activate a “Tri-Agonist” physiological response. While Tirzepatide acts upon the GIP and GLP-1 receptors to enhance insulin secretion and improve insulin sensitivity, the addition of Cagrilintide introduces a third vector: amylin receptor agonism. Research indicates that this third pathway is crucial for overcoming the “efficacy plateau” often observed in single or dual-agonist studies. The amylin component acts centrally in the hindbrain (area postrema) to induce satiety signals that are mechanically distinct from GLP-1 pathways, offering a multi-layered approach to appetite regulation modelling.

Secondary Research Finding: Adipose Tissue Remodelling Cagritirz is extensively utilised in studies focusing on white adipose tissue (WAT) browning and lipid oxidation. The GIP component of the blend has been shown in murine models to improve the buffering capacity of adipose tissue, reducing circulating triglycerides and preventing ectopic fat accumulation in the liver. Concurrently, the amylin analogue component is being investigated for its potential to increase energy expenditure via thermogenesis. This dual-action—improving lipid storage efficiency while simultaneously promoting oxidation—makes Cagritirz a primary candidate for research into non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome.

Tertiary Research Finding: Gastric Kinetics and Ileal Brake In-vivo studies have demonstrated that Cagritirz exerts a profound influence on gastric motility. The presence of the amylin analogue significantly potentiates the gastric slowing effect of the GLP-1 agonist. This interaction is critical for researchers studying the “ileal brake”—a feedback mechanism that inhibits upper gastrointestinal motility. Data suggests that the combination therapy results in a smoother, more sustained reduction in gastric emptying compared to monotherapy, leading to a more stable blunting of post-prandial glucose spikes without the compensatory hypoglycaemia often seen in insulin-based interventions.

Long-term Genomic and Safety Observations Current longitudinal research is focused on the gene expression profiles of pancreatic islet cells under the influence of this specific blend. Preliminary transcriptomic analysis suggests that the GIP component may upregulate anti-apoptotic genes (such as Bcl-2), potentially offering a protective mechanism against beta-cell exhaustion. Researchers are monitoring these markers to determine if the blend offers a superior safety profile for islet health compared to traditional sulfonylureas or GLP-1 monotherapies.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC). The blend is rigorously tested to ensure the ratio of Cagrilintide to Tirzepatide is precise and that no synthesis by-products remain.

• Appearance: The pen contains a clear, colourless, sterile liquid free from particulate matter.

• Precision: The pen device is calibrated for high-precision micro-dosing, allowing researchers to administer exact volumes essential for calculating ED50​ (median effective dose) values.

• Storage: The product must be maintained at a constant temperature of 2∘C to 8∘C to prevent peptide degradation.

Storage and Shipping Guidelines

Refrigeration and Shelf Life

The Cagritirz 15mg Pen utilises a bacteriostatic formulation to ensure stability; however, it is strictly a cold-chain product. Upon receipt, it must be stored in a refrigerator (2∘C to 8∘C). The shelf life of the sealed pen is 12 months. Once the pen is used for an experiment, the introduction of atmospheric oxygen accelerates potential degradation; therefore, it is recommended to complete all associated trials within 28 days of breaking the seal.

Shipping Stability

The molecular stability of Cagritirz allows it to withstand ambient temperatures for up to 28 days.

This resilience is due to the specific pH buffering of the solution, ensuring the product arrives at your laboratory with its bioactivity fully intact.

Freezing Warning Do not freeze

The complex tertiary structure of the large peptide chains in Cagritirz is susceptible to denaturation upon freezing. Crystallisation of the water solvent can shear these bonds, permanently destroying the peptide’s binding affinity. Furthermore, the expansion of the liquid can compromise the mechanical integrity of the pen’s glass cartridge.

Why Choose the Peptide Pro 3ml Pen Format?

The Cagritirz 15mg Pen is engineered for the modern research laboratory, where reproducibility is the gold standard. Traditional methods of mixing two separate lyophilised powders (Cagrilintide and Tirzepatide) introduce significant risks of dosing error and contamination.

Our pre-formulated pen removes these variables. It provides a sterile, verified ratio of the two compounds, ensuring that every subject in your study receives an identical molecular composition. This consistency is vital for publishing high-impact data in peer-reviewed journals.

For researchers interested in isolating the specific mechanisms of the individual components or related blends, we recommend examining:

• Cagrireta 15mg: (For Retatrutide-based combination research).

• Cagrilintide 10mg:  (For pure Amylin analogue control studies).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection, therapeutic use, or diagnostic procedures. The information provided above is for educational and scientific reference only. Purchase is restricted to verified research institutions and qualified individuals. Any evidence of intended misuse for human application will result in immediate order cancellation and restrictions on future access, in compliance with UK regulations regarding research chemicals.